Trial Profile
Phase II Study of Clofarabine and High-Dose Melphalan Conditioning Prior to Allogeneic Haematopoietic Cell Transplantation for Myelodysplasia or Acute Leukaemia in Remission
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 18 Mar 2024
Price :
$35
*
At a glance
- Drugs Clofarabine (Primary) ; Melphalan (Primary) ; Sirolimus; Tacrolimus; Tacrolimus
- Indications Acute myeloid leukaemia; Acute myelomonocytic leukaemia; Chronic myelomonocytic leukaemia; Graft-versus-host disease; Myelodysplastic syndromes; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Biomarker; Therapeutic Use
- 13 Mar 2024 Planned End Date changed from 30 Dec 2023 to 30 Dec 2024.
- 07 Feb 2023 Planned End Date changed from 30 Dec 2022 to 30 Dec 2023.
- 07 Feb 2023 Planned primary completion date changed from 30 Dec 2022 to 30 Dec 2023.